Ontogeny and the effects of exogenous and endogenous glucocorticoids on tight junction protein expression in ovine cerebral cortices.
Maternal glucocorticoid treatment reduces blood-brain permeability early, but not late in fetal development, and pretreatment with glucocorticoids does not affect barrier permeability in newborn lambs. In addition, endogenous increases in plasma cortisol levels are associated with decreases in blood-brain barrier permeability during normal fetal development. Therefore, we tested the hypotheses that development as well as endogenous and exogenous glucocorticoids alters the expression of tight junction proteins in the cerebral cortex of sheep. Cerebral cortices from fetuses at 60%, 70%, and 90% of gestation, newborn and adult sheep were snap frozen after four 6-mg dexamethasone or placebo injections were given over 48-h to the ewes and adult sheep. Lambs were treated similarly with 0.25 mg/kg-dexamethasone or placebo. Tight junction protein expression was measured by Western immunoblot. Claudin-1 was higher (P<0.05) in fetuses at 60% of gestation than in newborn and adult sheep. Claudin-5 was higher at 60% than 70% of gestation, and than in newborn and adult sheep. ZO-1 was higher in newborn than adult sheep. ZO-2 was higher at 90% gestation, in newborn and adult sheep than 60% gestation. Claudin-5 was higher in dexamethasone than placebo-treated lambs, and ZO-2 was higher in fetuses of dexamethasone than placebo-treated ewes at 90% gestation. ZO-2 expression demonstrated a direct correlation with increases in plasma cortisol during fetal development. We conclude that claudin-1, claudin-5, ZO-1, and ZO-2 expression exhibit differential developmental regulation, exogenous glucocorticoids regulate claudin-5 and ZO-2 in vivo at some, but not all ages, and increases in endogenous fetal glucocorticoids are associated with increases in ZO-2 expression, but not with occludin, claudin-1, claudin-5 or ZO-1 expression in ovine cerebral cortices.
The Warren Alpert Medical School of Brown University Department of Pediatrics Women and Infants' Hospital of Rhode Island 101 Dudley Street Providence, RI 02905-2499, USA.
Anna R
AR
Duncan
Grazyna B
GB
Sadowska
Barbara S
BS
Stonestreet
D000375:Aging / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000502:physiology; D002450:Cell Communication / Q000187:drug effects / Q000502:physiology; D002540:Cerebral Cortex / Q000187:drug effects* / Q000254:growth & development* / Q000648:ultrastructure; D062445:Claudin-1; D062507:Claudin-5; D003907:Dexamethasone / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D005333:Fetus / Q000196:embryology / Q000378:metabolism; D005938:Glucocorticoids / Q000378:metabolism / Q000494:pharmacology*; D008565:Membrane Proteins / Q000187:drug effects* / Q000378:metabolism; D010750:Phosphoproteins / Q000187:drug effects / Q000378:metabolism; D012756:Sheep / Q000254:growth & development* / Q000378:metabolism; D019108:Tight Junctions / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D062826:Zonula Occludens-1 Protein; D062827:Zonula Occludens-2 Protein
D062445:Claudin-1; D062507:Claudin-5; D005938:Glucocorticoids; D008565:Membrane Proteins; D010750:Phosphoproteins; D062826:Zonula Occludens-1 Protein; D062827:Zonula Occludens-2 Protein; D003907:Dexamethasone